Unanticipated Adverse Events With Tirzepatide: Three Cases Underscoring the Importance of Postmarketing Monitoring.
Publication/Presentation Date
10-1-2025
Abstract
Tirzepatide (Zepbound), a novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, demonstrates an additive effect, significantly enhancing insulin secretion compared to administering each hormone separately. The case reports presented here, detailing palpitations, musculoskeletal pain, and headaches following tirzepatide administration, raise important questions about the drug's postmarketing safety profile.
Volume
3
Issue
10
First Page
195
Last Page
195
ISSN
2755-1520
Published In/Presented At
Colorado, M., Gomez Miranda, J., & Arias-Morales, C. E. (2025). Unanticipated Adverse Events With Tirzepatide: Three Cases Underscoring the Importance of Postmarketing Monitoring. JCEM case reports, 3(10), luaf195. https://doi.org/10.1210/jcemcr/luaf195
Disciplines
Medicine and Health Sciences
PubMedID
40895495
Department(s)
Fellows and Residents
Document Type
Article